Phase Ia study of anti-NAPI2B antibody–drug conjugate lifastuzumab vedotin DNIB0600A in patients with non–small cell lung cancer and platinum-resistant ovarian cancer

1. Gerber, D.E.
2. Infante, J.R.
3. Gordon, M.S.
4. Goldberg, S.B.
5. Martín, M.
6. Felip, E.
7. Garcia, M.M.
8. Schiller, J.H.
9. Spigel, D.R.
10. Cordova, J.
11. Westcott, V.
12. Wang, Y.
13. Shames, D.S.
14. Choi, Y.
15. Kahn, R.
16. Dere, R.C.
17. Samineni, D.
18. Xu, J.
19. Lin, K.
20. Wood, K.
21. Royer-Joo, S.
22. Lemahieu, V.
23. Schuth, E.
24. Vaze, A.
25. Maslyar, D.
26. Humke, E.W.
27. Burris, H.A.
28. Show all authors +

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1158/1078-0432.CCR-18-3965 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus